What's in Neal D. Bhatia, MD's pipeline?

Neal D. Bhatia, MD has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Neal D. Bhatia, MD's portfolio?

Top competitors by shared drug class: Actavis Inc., Goldman, Butterwick, Fitzpatrick and Groff, LEO Pharma.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/neal-d-bhatia-md.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Neal D. Bhatia, MD — Portfolio Competitive Intelligence Brief

Neal D. Bhatia, MD pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
ingenol mebutate 0.05% gel	ingenol mebutate 0.05% gel	marketed	Protein kinase C activator	Protein kinase C (PKC)	Dermatology/Oncology

Therapeutic area mix

Dermatology/Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Actavis Inc. · 1 shared drug class
Goldman, Butterwick, Fitzpatrick and Groff · 1 shared drug class
LEO Pharma · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Neal D. Bhatia, MD:

Cite this brief

Drug Landscape (2026). Neal D. Bhatia, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/neal-d-bhatia-md. Accessed 2026-05-16.